Pasithea Therapeutics Faces Uncertainty Despite Positive Trial Data

Pasithea Therapeutics shares are trading lower despite announcing positive tablet pharmacokinetic data in their Phase 1/1b trial. Uncertainty over future trial outcomes and regulatory approvals may affect investor confidence.